Nasal Closure for Hereditary Hemorrhagic Telangiectasia (HHT): (The Lund Modification of Young’S Procedure)



Nasal Closure for Hereditary Hemorrhagic Telangiectasia (HHT): (The Lund Modification of Young’S Procedure)


Valerie J. Lund



INTRODUCTION

Hemorrhagic telangiectasia (HHT) is an inherited disorder characterized by telangiectasia with endothelium deficient in muscle or elastic tissue. It was first described in the 1860s by Sutton (1864) and Babington (1865) although the names of Osler, Rendu, and Weber (1901, 1896, and 1907) are more commonly associated with the condition that is autosomal dominant and non-sex linked. Genetic mutations in Cr 9,12,5 with signal transforming growth factor (TGF-beta) cause abnormal development of blood vessels.

HHT is found throughout the world with an incidence of 12.5 to 15.6 per 1,000 of the population, but there are significant geographical variations. The condition can affect any part of the body, in particular cutaneous and mucosal surfaces where the small telangiectasia may be readily seen. However, in organs such as the liver, lung, and brain, larger arteriovenous malformations may be found, which, in the lungs, can lead to significant shunting.










Jun 15, 2016 | Posted by in OTOLARYNGOLOGY | Comments Off on Nasal Closure for Hereditary Hemorrhagic Telangiectasia (HHT): (The Lund Modification of Young’S Procedure)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access